Pieris Pharmaceuticals Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
50
- Stock Symbol
-
PIRS
- Investments
-
2
- Share Price
-
$17.03
- (As of Thursday Closing)
Pieris Pharmaceuticals General Information
Description
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Contact Information
Website
www.pieris.comCorporate Office
- 225 Franklin Street
- Floor 26
- Boston, MA 02110
- United States
Corporate Office
- 225 Franklin Street
- Floor 26
- Boston, MA 02110
- United States
Pieris Pharmaceuticals Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.03 | $17.49 | $6.20 - $27.20 | $22.5M | 1.32M | 139K | -$18.69 |
Pieris Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | (6,132) | (14,527) | 19,776 | 162,820 |
| Revenue | 20,872 | 42,810 | 25,902 | 31,418 |
| EBITDA | (24,808) | (24,613) | (31,218) | (43,374) |
| Net Income | (23,818) | (24,543) | (33,277) | (45,738) |
| Total Assets | 25,051 | 38,680 | 95,490 | 153,560 |
| Total Debt | 0 | 0 | 13,103 | 14,890 |
Pieris Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Pieris Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
Pieris Pharmaceuticals Competitors (29)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| Molecular Partners | Formerly VC-backed | Zurich, Switzerland | 000 | 00000 | 00000000 | 00000 |
| Inhibrx | Formerly VC-backed | La Jolla, CA | 000 | 00000 | 000000&0 | 00000 |
| BioLegend | Formerly Accelerator/Incubator backed | San Diego, CA | 000 | 000000&0 | ||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom | 000 | 00.000 | 000000000 | 00.000 |
Pieris Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Pieris Pharmaceuticals Patents
Pieris Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022253567-A1 | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) | Pending | 08-Apr-2021 | 00000000000 | |
| CA-3214220-A1 | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) | Pending | 08-Apr-2021 | 00000000000 | |
| US-20240228562-A1 | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) | Pending | 08-Apr-2021 | 00000000000 | |
| EP-4320141-A1 | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) | Pending | 08-Apr-2021 | 00000000000 | |
| CA-3211591-A1 | Her2/4-1bb bispecific fusion proteins for the treatment of cancer | Pending | 23-Mar-2021 | A61P35/00 |
Pieris Pharmaceuticals Executive Team (19)
| Name | Title | Board Seat |
|---|---|---|
| Stephen Yoder JD | President, Chief Executive Officer & Board Member | |
| Thomas Bures | Senior Vice President & Chief Financial Officer, Finance | |
| Hitto Kaufmann | Chief Scientific Officer & Senior Vice President | |
| Shane Olwill Ph.D | Executive & Senior Vice President | |
| Safiya Vasilyev | Executive Assistant To Chief Executive Officer |
Pieris Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Ann Barbier Ph.D | Self | Board Member | 000 0000 |
| James Geraghty JD | Self | Chairman & Board Member | 000 0000 |
| Matthew Sherman MD | Self | Board Member | 000 0000 |
| Maya Said | Self | Board Member | 000 0000 |
| Michael Richman | Self | Board Member | 000 0000 |
Pieris Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Pieris Pharmaceuticals Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Palvella Therapeutics | 24-Jul-2024 | 0000000 00 | Drug Discovery | ||
| Marika | 18-Dec-2014 | Merger/Acquisition | Social/Platform Software | 0000000 0 |
Pieris Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated June, 13, 2021
33.63 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
Percentile
Biotechnology
Subindustry
00 of 427
Rank
Percentile
Pieris Pharmaceuticals FAQs
-
When was Pieris Pharmaceuticals founded?
Pieris Pharmaceuticals was founded in 2001.
-
Who is the founder of Pieris Pharmaceuticals?
Arne Skerra Ph.D is the founder of Pieris Pharmaceuticals.
-
Who is the CEO of Pieris Pharmaceuticals?
Stephen Yoder JD is the CEO of Pieris Pharmaceuticals.
-
Where is Pieris Pharmaceuticals headquartered?
Pieris Pharmaceuticals is headquartered in Boston, MA.
-
What is the size of Pieris Pharmaceuticals?
Pieris Pharmaceuticals has 50 total employees.
-
What industry is Pieris Pharmaceuticals in?
Pieris Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Pieris Pharmaceuticals a private or public company?
Pieris Pharmaceuticals is a Public company.
-
What is Pieris Pharmaceuticals’s stock symbol?
The ticker symbol for Pieris Pharmaceuticals is PIRS.
-
What is the current stock price of Pieris Pharmaceuticals?
As of 12-Sep-2024 the stock price of Pieris Pharmaceuticals is $17.03.
-
What is the current market cap of Pieris Pharmaceuticals?
The current market capitalization of Pieris Pharmaceuticals is $22.5M.
-
What is Pieris Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Pieris Pharmaceuticals is $20.9M.
-
Who are Pieris Pharmaceuticals’s competitors?
CytomX Therapeutics, Molecular Partners, Inhibrx, BioLegend, and Immunocore Holdings are some of the 29 competitors of Pieris Pharmaceuticals.
-
What is Pieris Pharmaceuticals’s annual earnings per share (EPS)?
Pieris Pharmaceuticals’s EPS for 12 months was -$18.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
